Wellington Management Group
FBRX

Wellington Management Group’s Forte Biosciences FBRX Stock Holding History

Wellington Management Group’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$938K Buy
44,156
+14,665
+50% +$348K ﹤0.01% 1760
2026
Q1 		$764K Buy
+29,491
New +$850K ﹤0.01% 1722

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Wellington Management Group's FBRX Position: Q2 2026 in Review

Wellington Management Group increased its Forte Biosciences (FBRX) stake by 50% in Q2 2026, buying an estimated $348K and bringing the position to 44,156 shares worth $938K. The position accounts for ﹤0.01% of the portfolio, ranked #1760.

Wellington Management Group first reported a position in FBRX in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Wellington Management Group held 44,156 shares of Forte Biosciences worth $938K as of Q2 2026.
  • Wellington Management Group bought 14,665 Forte Biosciences shares in Q2 2026, an estimated $348K.
  • Forte Biosciences made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1760 holding.
  • Wellington Management Group first reported a position in Forte Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.